In the context of being part of ICH, the biopharmaceutical industry in China has entered a new era with emerging challenges: how to develop the next generation of innovative therapeutic biologics to stand out from the competition? How to speed up from R&D to regulatory submission with differentiated product pipelines (antibodies, therapeutic vaccines, cell and gene therapy products, virus products)?How to make compliance with regulatory requirements when making bioprocess improvement changes? How to accelerate the clinical development of innovative biopharma and biosimilars? What factors should be considered in the mass production and plant construction of biopharma?

As the most influential annual biopharma event in China, the 7th BioCon 2020 will be held on July 7-9, in CECIS-Shanghai, with higher speaker quality, deeper insights, cutting-edge regulation interpretation, and real technical case studies from leading biopharma players. Comprehensive topics will cover from drug discovery to IND, from the laboratory test to industrialization, from preclinical development to clinical development, from process development to commercial production, from NDA to commercial launch . The event aims to build a professional platform for regulatory discussions, technical exchanges, product displays, project cooperation from China and overseas, hence helping industry players to succeed in the fast growing Chinese biopharmaceutical industry!